Dr. Ari Melnick and team have published a breakthrough finding in Nature Immunology that has identified Smc3 as a critical gene in the development of the body’s immune response (B cells).
The awards are given to “promising early-career projects aimed at addressing unmet needs in cancer research.”
Results from an international Phase 3 clinical trial have led to the U.S. Food and Drug Administration’s approval of oral azacytidine (Onureg) as a maintenance therapy for AML, which is now being used as part of standard patient care.
Dr. Ari Melnick and colleagues have published breakthrough findings that show certain histone H1 mutations are drivers of lymphoma.
Dr. Landau was one of six scientists from around the world to receive this prestigious honor. He will receive $300,000 in discretionary funds to be spent over four years for basic biomedical research.
A development program for junior faculty, LAMP provides participants with critical tools to accomplish their primary career goals as academicians in the field of medicine.
Dr. Melnick is being recognized for “significant research contributions to the treatment of acute myeloid leukemia through an improved understanding of epigenetics.”
Initiated in 2002, the award is given to fellows within the Weill Department of Medicine who have performed outstanding research. This year's finalists were presented at Medicine Grand Rounds on June 17.
Patients with the most common type of metastatic pancreatic cancer showed improved results when treated with a combination of an investigational drug, an immunotherapy drug, and chemotherapy.
In response to the COVID-19 pandemic, faculty from across the Weill Department of Medicine have been pursuing critical research.
